Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck & Co., Inc
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability, and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus
Main objective: (1) To assess the effect of treatment with MK-0893 compared to placebo on 24-hour weighted mean glucose (WMG). (2) To assess the safety and tolerability of MK-0893.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pediatric Dose-Ranging of Mometasone Furoate MDI
To demonstrate the dose-related efficacy by evaluating morning lung function at the end of the dosing interval (AM pre-dose percent predicted forced expiratory volume in one second [FEV1]) after 12 we...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pembrolizumab in advanced renal cell carcinoma
1. To estimate the objective response rate (ORR) per RECIST 1.1 as assessed by BICR in subjects with clear cell RCC. 2. To estimate the ORR per RECIST 1.1 as assessed by BICR in subjects with non-cle...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
NovaCardia, Inc. (A wholly owned subsidiary of Merck & Co., Inc.)
MAJ Il y a 5 ans
A multicenter, randomized, double-blind, placebo-controlled study of the hemodynamic effects of rolofylline injectable emulsion in the treatment of patients with heart failure
The objectives of this study are to estimate the effects of rolofylline, alone in addition to loop diuretic therapy, on pulmonary capillary wedge pressure, as well as other hemodynamic parameters, and...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resection
- To prospectively assess whether post-operative adjuvant therapy with pembrolizumab improves recurrence-free survival, as compared to placebo in high-risk patients with complete resection of Stage II...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Study of MK-1986 (tedizolid phosphate) in children 3 mo to <12 yr with acute bacterial skin and skin structure infections (ABSSSI)
(1) The primary objective is to use descriptive statistics to evaluate the safety of intravenous (IV) and/or oral 6- or 10-day tedizolid phosphate with 10- or 14-day IV and/or oral comparator in subje...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
Estudio polisomnográfico de fase IIb, multicéntrico, aleatorizado, doble ciego, controlado con placebo, cruzado, adaptativo de dos periodos para evaluar la seguridad y la eficacia de MK-6096 en pacientes con insomnio primario" "A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period Adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of MK-6096 in Patients with Primary Insomnia
1.Evaluar la eficacia de MK-6096 en comparación con placebo en lo que respecta a mejorar la eficiencia del sueño (ES) según lo determinado mediante polisomnografía (PSG) la noche 1 y al final de las 4...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase 3 study in Patients with Type 2 Diabetes Mellitus Studio di fase III su pazienti affetti da diabete mellito di tipo 2
After 24 weeks, to assess the effect of treatment with MK-3102 compared with placebo on A1C. To assess the safety and tolerability of MK-3102. Valutare l’effetto sulla A1C del trattamento con M...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Phase IIa Randomized, Placebo-Controlled, Parallel Group, Clinical Trial to Study the Efficacy and Safety of MK-2866 in Women with Moderate to Severe Chronic Obstructive Pulmonary Disease Participating in Pulmonary Rehabilitation" Ensayo clínico de fase IIA, aleatorizado, controlado con placebo y de grupos paralelos para estudiar la eficacia y seguridad de MK-2866 en mujeres con Enfermedad Pulmonar Obstructiva Crónica de moderada a grave que estén participando en una rehabilitación pulmonar
En mujeres de edades comprendidas entre 40 y 75 años con enfermedad pulmonar obstructiva crónica (EPOC) que participen en una rehabilitación pulmonar: Objetivo 1: investigar el efecto del tratamiento ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck)
MAJ Il y a 5 ans
MK-3475 vs. Docetaxel in Second-Line Non-Small Cell Lung Cancer
1) To compare the overall survival of previously treated subjects with nonsmall cell lung cancer in the strongly positive PDL1 stratum treated with MK3475 compared to docetaxel. 2) To compare progres...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
4
5
6
7
8
9
10
11
12
13
Suivant